<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="644">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529525</url>
  </required_header>
  <id_info>
    <org_study_id>IVERCORCOVID19MSPICC</org_study_id>
    <nct_id>NCT04529525</nct_id>
  </id_info>
  <brief_title>Ivermectin to Prevent Hospitalizations in COVID-19</brief_title>
  <acronym>IVERCORCOVID19</acronym>
  <official_title>Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiología de Corrientes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiología de Corrientes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a single-center, prospective, randomized, double-blind, placebo-controlled study
      carried out by the Ministry of Public Health of the Province of Corrientes, Argentina, in
      coordination with the Corrientes Institute of Cardiology &quot;Juana F. Cabral&quot;. Patients who meet
      all the inclusion criteria and none of the exclusion criteria are randomized via the web
      system to receive placebo or ivermectin. The need for hospitalization in patients with
      COVID-19 is assessed as the primary end point. As secondary end points are evaluated: time to
      hospitalization (in days); use of invasive mechanical ventilation; time to invasive
      mechanical ventilation (in days); dialysis; all-cause mortality; negative of the swab at 3 ±
      1 days and 12 ± 2 days after entering the study and ivermectin safety.

      Intermediate internal analyzes of study objectives and serious adverse events will be
      performed, including 125; 250 and 375 patients in order to assess the possible need for early
      termination of the study. For these intermediate internal analyzes, the Haybittle-Peto rule
      will be followed, therefore a value of p &lt;0.001 will be considered significant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be carried out in the province of Corrientes, in the Argentine Republic. All
      patients must be domiciled in this province. In the province of Corrientes, the care of
      patients with COVID19 is in charge of a single group of professionals (Crisis Committee) and
      patients who require hospitalization will be carried out in a single hospital destined for
      this purpose
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Hospitalization will be considered when at least 24 hours have elapsed in a health institution, in any of its services.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hospitalization</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Number of days elapsed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Use of invasive mechanical ventilation support in each arm</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>All patients who are connected to invasive mechanical ventilation support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to invasive mechanical ventilation support</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Number of days elapsed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dialysis in each arm</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>All patients who require temporary or permanent renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>Death of the patient, from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative of the swab at 3±1 days and 12±2 days after entering the study</measure>
    <time_frame>At days 3±1 and 12±2</time_frame>
    <description>Negative Nasal Swab Using Polymerase Chain Reaction Technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>through study completion, an average of 30 days</time_frame>
    <description>According to the adverse events that patients may present.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:
More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dose of placebo in patients who are randomized to the this depends on the weight of the patient:
More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age who reside in the province of Corrientes at the time of
             diagnosis;

          -  Confirmed diagnosis of COVID-19 by polymerase chain reaction test for detection of
             SARS-CoV2 in the last 48 hours;

          -  In the case of women of childbearing age, they must be using a contraceptive method of
             proven efficacy and safety (barrier, hormonal or permanent contraceptives) for at
             least 3 months prior to inclusion in the present study and for the entire period of
             time for the duration of the study and until at least 30 days after the end of this
             study. A woman will be considered to have no reproductive capacity if she is
             postmenopausal (at least 2 years without her menstrual cycles) or if she has undergone
             surgical sterilization (at least one month before the time of inviting her to
             participate in this study);

          -  Weight at the time of inclusion greater than 48,000 kilograms;

          -  That they sign the informed consent for participation in the study.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women;

          -  Known allergy to ivermectin or some of the components of ivermectin tablets or
             placebo;

          -  Current use of home oxygen;

          -  That require hospitalization due to COVID-19 at the time of diagnosis or history of
             hospitalization for COVID-19;

          -  Presence of mal-absorptive syndrome;

          -  Presence of any other concomitant acute infectious disease;

          -  Known history of severe liver disease, for example liver cirrhosis;

          -  Need or use of antiviral drugs at the time of admission for another viral pathology
             other than COVID-19;

          -  Need or use of hydroxychloroquine or chloroquine;

          -  Use of ivermectin up to 7 days prior to randomization;

          -  Patients on dialysis or who have required it in the last 2 months or who plan to do it
             in the next 2 months;

          -  Current participation or in the last 30 days in a research study that has included the
             administration of a drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rodrigo Zoni, Dr</last_name>
    <phone>+5493794269233</phone>
    <email>rodrizoni@yahoo.com.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julio Vallejos, Dr</last_name>
    <phone>+543794788655</phone>
    <email>juliovallejos@funcacorr.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ministry of Public Health of the Province of Corrientes</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Zoni, Dr</last_name>
      <phone>+54379154269233</phone>
      <email>rodrizoni@yahoo.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Julio Vallejos, Dr</last_name>
      <phone>+543794788655</phone>
      <email>juliovallejos@funcacorr.org.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Julio Vallejos, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Zoni, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Bangher, Dra</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvina Villamandos, Dra</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelina Bobadilla, Dra</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian Plano, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Achinelli, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Campias</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Ojeda, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector A Gugliermone</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Andino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia E Ruiz Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Kawerin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Farizano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria F Medina</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvina D Dellamea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia C Aquino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor A Flores</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia E Chaparro Campias</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolina N Martemucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan E Segovia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Castillo Ruveda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria M Vernengo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvana M Martinez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elba Meza</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria G Aguirre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <results_reference>
    <citation>Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145. Review.</citation>
    <PMID>32293834</PMID>
  </results_reference>
  <results_reference>
    <citation>González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans--a mini-review. AAPS J. 2008;10(1):42-6. doi: 10.1208/s12248-007-9000-9. Epub 2008 Jan 25. Review.</citation>
    <PMID>18446504</PMID>
  </results_reference>
  <results_reference>
    <citation>Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, Kong BW, Jans DA, Beer M, Haller O, Schwemmle M. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016 Mar 18;6:23138. doi: 10.1038/srep23138. Erratum in: Sci Rep. 2016 May 09;6:25428.</citation>
    <PMID>26988202</PMID>
  </results_reference>
  <results_reference>
    <citation>Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, Jans DA, Kehn-Hall K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res. 2013 Dec;100(3):662-72. doi: 10.1016/j.antiviral.2013.10.004. Epub 2013 Oct 22.</citation>
    <PMID>24161512</PMID>
  </results_reference>
  <results_reference>
    <citation>Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, Vasudevan SG, Jans DA. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013 Sep;99(3):301-6. doi: 10.1016/j.antiviral.2013.06.002. Epub 2013 Jun 14.</citation>
    <PMID>23769930</PMID>
  </results_reference>
  <results_reference>
    <citation>Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012 May 1;443(3):851-6. doi: 10.1042/BJ20120150.</citation>
    <PMID>22417684</PMID>
  </results_reference>
  <results_reference>
    <citation>Chi NC, Adam EJ, Adam SA. Sequence and characterization of cytoplasmic nuclear protein import factor p97. J Cell Biol. 1995 Jul;130(2):265-74.</citation>
    <PMID>7615630</PMID>
  </results_reference>
  <results_reference>
    <citation>Görlich D, Mattaj IW. Nucleocytoplasmic transport. Science. 1996 Mar 15;271(5255):1513-8. Review.</citation>
    <PMID>8599106</PMID>
  </results_reference>
  <results_reference>
    <citation>Rowland RR, Chauhan V, Fang Y, Pekosz A, Kerrigan M, Burton MD. Intracellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation during infection and after expression as a recombinant protein in vero cells. J Virol. 2005 Sep;79(17):11507-12.</citation>
    <PMID>16103202</PMID>
  </results_reference>
  <results_reference>
    <citation>Timani KA, Liao Q, Ye L, Zeng Y, Liu J, Zheng Y, Ye L, Yang X, Lingbao K, Gao J, Zhu Y. Nuclear/nucleolar localization properties of C-terminal nucleocapsid protein of SARS coronavirus. Virus Res. 2005 Dec;114(1-2):23-34. Epub 2005 Jun 29.</citation>
    <PMID>15992957</PMID>
  </results_reference>
  <results_reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 12, 2020</last_update_submitted>
  <last_update_submitted_qc>September 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ivermectin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

